SIHNV Composition Plan definition

SIHNV Composition Plan means this composition plan (ontwerp van een akkoord). "SIHNV Contingent Payment Undertakings" means the:
Sample 1Sample 2Sample 3
SIHNV Composition Plan means the draft composition plan (in Dutch: “ontwerpakkoord”) originally dated 15 February 2021, substantially in the form as submitted by SIHNV together with its application for the SoP Proceedings dated 15 February 2021 and as may be amended until the court hearing scheduled pursuant to Section 255(1)(2°) of the Dutch Bankruptcy Act (in Dutch: “Faillissementswet”);
Sample 1Sample 2
SIHNV Composition Plan means the composition plan (ontwerp van akkoord) pursuant to Section 252 of the Dutch Bankruptcy Act (Faillissementswet), to be as offered by SIHNV to its creditors (as may be amended) and as accepted by them the committee of representation (commissie van vertegenwoordiging) in the court hearing scheduled pursuantto Section 255(1)(2o) of the Dutch Bankruptcy Act and confirmed (gehomologeerd) by the competent court in a final and unappealable judgment (in kracht van gewijsde);
Sample 1

Examples of SIHNV Composition Plan in a sentence

  • This Schedule sets out the principles for the valuation of the Claims of each Distribution Creditor, which shall be their Claim Value for the purposes of this SIHNV Composition Plan.

  • Finally, it would cause their Claim Values to change over time, which would complicate the calculation of the settlement distributions offered pursuant to this SIHNV Composition Plan (which is expected to occur over time as well, rather than at a single interval).1.9 Therefore, with a view to efficiency and consistency, the accrual of statutory interest is not taken into account for the Claim Values of the SIHNV MPC Relevant Claims.

  • Any Claim for payment from the SoP Settlement Fund or Reserve Fund arising from this SIHNV Composition Plan shall be subject to an expiry period (vervaltermijn) which ends on the Bar Date.

  • Pursuant to the foregoing, and taking into account the measures as further described in the SRF and Claims Administration Conditions, the performance of this SIHNV Composition Plan is sufficiently safeguarded (voldoende gewaarborgd).

  • This Part A (Explanatory Memorandum) and Part B (Composition Plan) set out below should be read in conjunction with one another and constitute the same SIHNV Composition Plan.

  • The payment thereof does not concern an unsecured non-preferred Claim, but instead an estate debt (boedelschuld), and therefore falls outside the scope of the SoP and this SIHNV Composition Plan.

  • This SIHNV Composition Plan is accessible on www.steinhoffsettlement.com.

  • This SIHNV Composition Plan and any non-contractual obligation arising out of or in connection with it shall be governed and construed exclusively in accordance with Dutch law.

  • SIHNV believes that this SIHNV Composition Plan represents the best achievable settlement offer to its creditors.The claims of the Distribution Creditors have been valued in accordance with the Valuation Principles.

  • No SoP Creditor may assign any of its rights or transfer any of its rights or obligations arising under this SIHNV Composition Plan.

Related to SIHNV Composition Plan

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Product Candidate means each biological and drug candidate, compound or other device or product being developed, labeled, manufactured, marketed, sold and/or distributed by the Company or a Company Subsidiary, or regarding which the Company or a Company has rights, and including any such biological and drug candidate, compound or product that has received Marketing Approval.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Step therapy protocol means a protocol or program that establishes the specific

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Edible cannabis product means cannabis product that is intended to be used, in whole or in part, for human consumption, including, but not limited to, chewing gum, but excluding products set forth in Division 15 (commencing with Section 32501) of the Food and Agricultural Code. An edible cannabis product is not considered food, as defined by Section 109935 of the Health and Safety Code, or a drug, as defined by Section 109925 of the Health and Safety Code.

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Diagnostic source assembly means the tube housing assembly with a beam-limiting device attached.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Assistive technology device means any item, piece of equipment, or product system that is used to increase, maintain, or improve the functional capacities of a child with a disability.

  • Clinical Study means a Xxxxx 0 Xxxxx, Xxxxx 2 Study, Phase 3 Study, Post-Marketing Study, Supplemental Study or other study (including a non-interventional study) in humans to obtain information regarding the product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product.

  • Manufacturing Technology means any and all patents, patent applications, know-how, and all intellectual property rights associated therewith that are owned or controlled by Licensor, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno-associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Development Plan has the meaning set forth in Section 3.2.

  • Development Plans means a coherent set of operations defined and financed exclusively by the OCTs in the framework of their own policies and strategies of development, and those agreed upon between an OCT and the Member State to which it is linked;

  • DMF means a drug master file, as provided for in 21 CFR § 314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • in vitro diagnostic medical device means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, software or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.